Affiliation:
1. Department of Neurosciences, Reproductive and Odontostomatological Sciences University of Naples “Federico II” Naples Italy
2. Department of Stereotactic and Functional Neurosurgery Faculty of Medicine and University Hospital of Cologne, University of Cologne Cologne Germany
Abstract
AbstractIntroductionSpinal cord stimulation (SCS) is currently used for the management of pain of different origin, and since its inception, many waveforms have been developed. Some patients experience no pain relief already during SCS trial, while other patients go through a loss of efficacy due to habituation after a variable period of satisfying pain control. Our retrospective study represents the first report exploring the potential role of 10 kHz stimulation as rescue therapy for patients who did not benefit not only from conventional stimulation but even from other waveforms during SCS trial or follow‐up.MethodsThis study was conducted in Germany; we retrospectively enrolled patients with no pain relief during SCS trial or with loss of efficacy of other waveforms over time; and we recorded visual analogic scale (VAS), Oswestry Disability Index (ODI), and daily opioid consumption expressed as morphine milligram equivalents (MME), right before and 12 months after the switching to 10 kHz simulation.ResultsThe rate of successful switching to 10 kHz stimulation was comparable in patients enrolled during the SCS trial and during the follow‐up (43% vs. 40%, respectively); notably, the highest rate of failed rescue was recorded in case of persistent spinal pain syndrome (PSPS) II. Patients who responded to the switching showed a significant improvement in VAS and ODI after 12 months of treatment compared to baseline (3.6 ± 1.0 vs. 8.2 ± 0.9, p < 0.00001 and 34.0 ± 7.8 vs. 64.3 ± 8.7, p < 0.0001, respectively), whereas there was no reduction in the consumption of opioids in terms of MME (3 (0–16) vs. 5 (0–8.75), p = 0.1003).ConclusionsRescue therapy with 10 kHz stimulation could be an important strategy to avoid SCS explant in both patients non‐responsive during trial or experiencing a loss of efficacy during the years with other waveforms.